Current Weather
The Spy FM

Merck Halts Sale Of Niacin Drug In 40 Countries

Filed by KOSU News in Business.
January 11, 2013

Drugmaker Merck just stuck a fork in a vitamin-based drug to prevent heart disease and stroke.

The company is withdrawing Tredaptive, a long-acting pill combining niacin (No. 3 in the long list of B vitamins) and laropripant, a chemical that reduces the unpleasant skin flushing caused by high doses of niacin.

Tredaptive was never approved in the U.S. — the Food and Drug Administration rejected the drug under another name in 2008. But now Merck is taking the medicine off the market in 40 countries where it has been sold. The company also told doctors to stop prescribing it.

Merck said in December that a big study found the drug didn’t work. What’s more, people taking it had more serious side effects than those who got a placebo. People in both groups also got simvastatin (sold under the brand-name Zocor) to lower their bad cholesterol, or LDL.

Tredaptive seemed like a great idea — on paper.

Niacin is one of the few ways to boost good cholesterol, or HDL. People whose HDL is too low are at a higher risk of having heart attacks and strokes, even when their LDL is right where it ought to be.

Many people who take niacin for this reason can’t tolerate it, though. So a drug that had the good effects of niacin without the discomfort looked appealing.

The failure of Tredaptive has cast a pall on the whole idea that raising HDL with a drug can help patients avoid heart attacks and strokes.

Cleveland Clinic cardiologist Steven Nissen told Shots last month that he wasn’t willing to ditch the idea that boosting HDL would reduce heart disease. Nevertheless, he said then, the failure of Tredaptive represented “a serious blow to the theory.”

Merck’s withdrawal of the drug won’t put a dent in the fortunes of the company. Global sales amounted to a puny $13 million for the three quarters that ended last September. [Copyright 2013 National Public Radio]

Leave a Reply

5AM to 9AM Morning Edition

Morning Edition

For more than two decades, NPR's Morning Edition has prepared listeners for the day ahead with two hours of up-to-the-minute news, background analysis, commentary, and coverage of arts and sports.

Listen Live Now!

9AM to 10AM The Takeaway

The Takeaway

A fresh alternative in morning news, "The Takeaway" provides a breadth and depth of world, national and regional news coverage that is unprecedented in public media.

View the program guide!

10AM to 11PM On Point

On Point

On Point unites distinct and provocative voices with passionate discussion as it confronts the stories that are at the center of what is important in the world today. Leaving no perspective unchallenged, On Point digs past the surface and into the core of a subject, exposing each of its real world implications.

View the program guide!

Upcoming Events in your area (Submit your event today!)

Streaming audio and podcasts

Stream KOSU on your smartphone

Phone Streaming

SmartPhone listening options on this page are intended for many iPhones, Blackberries, etc. with low-cost software applications available to listen to our full-time web streams, both News on KOSU-1 and Classical on KOSU-2.

Learn more about our complete range of streaming services

We're perfecting the patient experience - Stillwater Medical Center